Showing results (61-70 of 121) with videos related to
Sort By:
Pageof 13
FEBS Letters|June 3, 1991
Rapid purification and characterisation of HIV-1 reverse transcriptase and RNaseH engineered to incorporate a C-terminal tripeptide alpha-tubulin epitopeD K Stammers, M Tisdale, S Court, et al.The American Journal of Psychiatry|November 1, 1989
Apparent phase advance in diurnal MHPG rhythm in depressionH E Gwirtsman, A E Halaris, A W Wolf, et al.AIDS Research and Human Retroviruses|August 24, 2000
HIV type 1 protease cleavage site mutations and viral fitness: implications for drug susceptibility phenotyping assaysL H Robinson, R E Myers, B W Snowden, et al.Frontiers in Endocrinology|June 3, 2021
Dimming the Powerhouse: Mitochondrial Dysfunction in the Liver and Skeletal Muscle of Intrauterine Growth Restricted FetusesAlexander L Pendleton, Stephanie R Wesolowski, Timothy R H Regnault, et al.Antimicrobial Agents and Chemotherapy|February 24, 2006
In vitro development of resistance to human immunodeficiency virus protease inhibitor GW640385P J Yates, R Hazen, M St Clair, et al.Sleep Medicine|November 1, 2003
Long-term follow-up of sleep disordered breathing in older adultsS Ancoli-Israel, P Gehrman, D F Kripke, et al.Journal of Clinical Microbiology|May 1, 1991
Evaluation of the new RapID-ANA II system for the identification of clinical anaerobic isolatesL M Marler, J A Siders, L C Wolters, et al.Journal of Clinical Microbiology|February 1, 1992
Comparison of five cultural procedures for isolation of Clostridium difficile from stoolsL M Marler, J A Siders, L C Wolters, et al.Journal of Acquired Immune Deficiency Syndromes (1999)|June 8, 2000
A novel genotype encoding a single amino acid insertion and five other substitutions between residues 64 and 74 of the HIV-1 reverse transcriptase confers high-level cross-resistance to nucleoside reverse transcriptase inhibitors. Abacavir CNA2007 International Study GroupA Rakik, M Ait-Khaled, P Griffin, et al.AIDS (London, England)|July 14, 2000
Absence of zidovudine resistance in antiretroviral-naive patients following zidovudine/lamivudine/protease inhibitor combination therapy: virological evaluation of the AVANTI 2 and AVANTI 3 studiesM Maguire, M Gartland, S Moore, et al.Pageof 13